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Table 1. Hypothesis 1
% denuded bone, analyzed at: Increase* in median pain score,
per 10% increase in denuded
bone, adjusted for age, gender,
BMI, bone edema score (95%CI)
Medial tibial surface 4.46 (1.45, 7.47)
Weightbearing medial femoral surface 5.24 (3.19, 7.28)
Medial tibial + weightbearing medial femoral surface 6.35 (3.10, 9.59)
Medial tibial + weightbearing medial femoral + patellar 6.19 (1.28, 11.10)
*signiﬁcant if 95%CI excludes 0.
Table 2. Hypothesis 2
% denuded bone, analyzed at: Age, gender, BMI, K/L grade,
bone edema score-adjusted OR*
per 10% increase in denuded bone
(95%CI)
Medial tibial surface 1.61 (1.07, 2.42)
Weightbearing medial femoral surface 1.49 (1.13, 1.95)
Medial tibial + weightbearing femoral 1.61 (1.15, 2.26)
Medial tibial + weightbearing medial femoral + patellar 2.44 (1.50, 3.96)
*signiﬁcant if 95%CI excludes 1.
A44 THE EFFECT OF CHONDROITIN SULFATE ON
STRUCTURE MODIFICATION IN PATIENTS WITH KNEE
OSTEOARTHRITIS: A META-ANALYSIS OF RANDOMIZED
PLACEBO-CONTROLLED TRIALS
M.C. Hochberg, M. Zhan, P. Langenberg. University of Maryland,
Baltimore, MD, USA
Purpose: To determine the effect of chondroitin sulfate on structure
modiﬁcation, as measured by change in the rate of decline in minimum
joint space width, in patients with osteoarthritis (OA) of the knee.
Methods: The authors searched MEDLINE from 1996 to 2007 to identify
articles on the effect of chondroitin sulfate on structure modiﬁcation in
patients with knee OA. The reference lists of systematic reviews and
meta-analyses were searched and authors were contacted to identify
additional studies. The primary outcome was the change in minimal joint
space width over one year. One person abstracted data on the change in
minimum joint space width in the placebo-treated and chondroitin sulfate-
treated groups. Whenever possible, we used data from the intention-
to-treat analyses for pooling. For studies of two years in duration, we
assumed that the change was linear over time. Results were summarized
for both the absolute difference between the chondroitin sulfate and
placebo-treated groups as well as the standardized mean difference
(effect size) using the pooled standard deviations. Fixed effects models
were used as the Q and I2 statistics showed no evidence of between-trial
heterogeneity. Sensitivity analyses were also performed.
Meta-analysis of randomized controlled trials of chondroitin sulfate for structure modiﬁcation
Author Chondroitin Sulfate Placebo Difference (mm/year) Effect Size
(Year) No. of
patients
Mean
decline
SD No. of
patients
Mean
decline
SD Mean (95%CI) SMD (95%CI)
Uebelhart
(1998)
14 −0.1 1.24 12 0.4 1.00 −0.50 (−1.36, 0.36) −0.43
(−1.21, 0.36)
Uebelhart
(2004)
39 0.04 0.83 39 0.32 1.12 −0.28 (−0.72, 0.16) −0.28
(−0.73, 0.16)
Michel
(2006)
150 −0.02 0.24 150 0.04 0.28 −0.06 (−0.12, 0.00) −0.23
(−0.46, 0.00)
Reginster
(2007)
309 0.05 0.26 313 0.12 0.27 −0.07 (−0.11, −0.03) −0.26
(−0.42, −0.11)
Summary 512 514 −0.07 (−0.10, −0.03) −0.26
(−0.38, −0.l4)
Results: Six reports of 4 placebo-controlled trials of chondroitin sulfate
in patients with knee OA that reported changes in joint space width were
identiﬁed, including 5 articles (3 that reported on the same trial) and 1
conference abstract. Two trials each were of one and two years in dura-
tion. Overall, the 4 trials enrolled a total of 1026 patients (512 randomized
to chondroitin sulfate and 514 to placebo) (see Table). One pilot study,
including only 26 patients, was published in 1998; the remaining three
trials were published in 2004 or later.
The meta-analysis of all 4 trials found a mean difference of 0.07mm per
year (95% conﬁdence intervals [CI] 0.03, 0.10) in favor of chondroitin
sulfate for retarding the decline in minimal joint space width (P< 0.0001).
This corresponds to an effect size of 0.26 (95%CI: 0.14, 0.38). Sensitivity
analyses excluding the trial published only in abstract form (Reginster
et al [2007]) or excluding the two small trials of only one year in duration
(Uebelhart et al [1998 and 2004]) showed similar signiﬁcant results.
Conclusions: This meta-analysis demonstrates a signiﬁcant small-to-
moderate effect of chondroitin sulfate as a structure modifying drug
for treatment of patients with knee OA as measured by slowing the
rate of decline in minimum joint space width. These results support
recent OARSI treatment recommendations for use of chondroitin sulfate
in patients with knee OA.
A45 INDIRECT COMPARISON OF CLINICAL EFFICACY ACROSS
COCHRANE REVIEWED PHYSIOTHERAPY INTERVENTIONS
FOR PATIENTS WITH OSTEOARTHRITIS: A META-ANALYSIS
WITH MIXED TREATMENT COMPARISONS
H. Lund Sr1, R. Christensen2, H. Bliddal2. 1Institute of Sports Science
and Clinical Biomechanics, Odense, DENMARK, 2The Parker Institute,
Frederiksberg, DENMARK
Purpose: There have been numerous of systematic reviews of interven-
tions designed to diminish pain and improve function for patients with
OA, but the comparable effectiveness of such interventions is unclear.
To assess the clinical efﬁcacy of physiotherapeutic (PT) modalities and
interventions available in library of Cochrane reviews, on the pain and
disability in patients with osteoarthritis (OA), applying data from published
systematic Cochrane reviews of RCTs would be a useful method.
Methods: The Cochrane Library was searched for Cochrane reviews
considering patients with OA and different physiotherapeutic interventions
with the aim of reducing pain, and disability. A meta-regression analysis
was applied, for the mixed treatment comparisons, applying the individual
study’s standardized mean difference (SMD) as outcome measure, for
pain and disability, respectively. The statistical random-effects model
was based on a restricted maximum likelihood (REML), mixed-effects
model procedure with intervention as ﬁxed- and trial as random-factor,
respectively. The within study variance was considered known for each
published RCT, based on the explicit SD’s presented in each of the
original Cochrane reviews. A negative SMD favors the intervention on
trial.
Results: The search with “osteoarthritis” in the title resulted in 35 re-
views. Reasons for exclusion was protocols (K = 12), pharmacological
treatments and surgery (K=15), withdrawn (K=1) and 1 study compared
two different kinds of treatment (K = 1). Thus, 6 Systematic Cochrane
Reviews were included in the meta-regression model (patients included,
N=3,016): Lateral wedged insoles (LWI, pain k = 1; disability k = 1),
electromagnetic ﬁeld therapy (EMF, pain k = 2; disability k = 2), exercise
(EXE, pain k = 17; disability k = 18), ultrasonic therapy (UST, pain k = 1;
disability k = 0), thermotherapy (THT, pain k = 1; disability k = 1), and
transcutaneous electrical nerve stimulation (TENS, pain k = 6, disability
k = 1).
Based on the indirect meta-analysis we were able to rank these 6 mutually
independent interventions according to the published efﬁcacy on pain;
data are presented in descending efﬁcacy (SMD) order with the corre-
sponding p-value: EMF (SMD: −1.13, p = 0.003); THT[cold] (SMD: −0.69,
p = 0.21); TENS (SMD: −0.45, p = 0.003); EXE (SMD: −0.43, p = 0.0001);
LWI (SMD: 0.31, p = 0.45); UST (SMD: 0.43, p = 0.34). According to the
published efﬁcacy on disability: THT[cold] (SMD: −1.96, p< 0.0001); EMF
(SMD: −0.81, p = 0.002); TENS (SMD: −0.60, p = 0.08); EXE (SMD: −0.34,
p< 0.0001); LWI (SMD: 0.30, p = 0.24).
Conclusions: Based on this mixed treatment comparison, we provide
quantitative evidence-based efﬁcacy ranking of the PT interventions cur-
rently available as an updated Cochrane review. Based on the reported
pain and disability reduction, it is highly evident (p< 0.0001) that exercise
therapy does beneﬁt the patient; although not necessarily with the largest
magnitude of efﬁcacy. Of the other therapies tested, both EMF and
TENS showed a relevant effect size of moderate statistical signiﬁcance
(p = 0.003 respectively p = 0.03) on pain. In addition, THT and EMF
showed a clinically relevant effect size on disability reduction (p< 0.0001
respectively p = 0.002). The present indirect-comparison provide the clin-
ician a review of the modalities to choose, accordingly LWI, UST might
not be effective in the treatment of osteoarthritis.
A46 TAI CHI IS EFFECTIVE IN TREATING KNEE
OSTEOARTHRITIS: A RANDOMIZED CONTROLLED TRIAL
C. Wang, C. Schmid, P. Hibberd, R. Kalish, R. Roubenoff, R. Rones,
A. Okparavero, T. McAlindon. Tufts Medical Center, Boston, MA, USA
Purpose: Knee osteoarthritis (KOA) is a major cause of pain and
functional impairment among elders and has no medical remedy. The
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pathophysiological basis of KOA is multifaceted and includes impaired
muscle function, reduced proprioceptive acuity, and the psychological
traits of chronic pain. Tai Chi is an ancient Chinese exercise that uses
an integrated mind-body approach to enhance muscle function, balance,
ﬂexibility, and reduce pain, depression and anxiety. Tai Chi may thus be
especially suited to the therapy of KOA.
Methods: We used a random number list to randomize 40 eligible indi-
viduals (age >55 yr, BMI 40 kg/m2 with knee pain on most days of the
previous month and tibiofemoral OA K/L grade 2) to Tai Chi (10 modiﬁed
forms from classical Yang style) or an attention control (stretching and
wellness education). The 60-minute intervention sessions occurred twice-
weekly for 12 weeks. The primary endpoint was change in the WOMAC
pain score (VAS) at 12 weeks. Secondary endpoints included WOMAC
function, patient and physician global assessments (VAS), timed chair
stand, balance tests, knee proprioception (Biometrics electrogoniometer),
depression (CES-D index), self-efﬁcacy, and health-related quality of life
(SF-36). We repeated these assessments at 24 and 48 weeks to test
durability of response. The Tai Chi and control groups were compared by
intention-to-treat using t-tests.
Table. Changes in primary and secondary outcomes
Variables Groups* Baseline At 12 week
Change
(95%CI)
P-Value
for D
between
group***
WOMAC-Pain VAS, 0–500mm Tai Chi 209.3
(58.5)
−157.3
(−198.5, −116)
0.0004
Control 220.4
(101)
−38.5
(−87.2, 10.3)
WOMAC-Physical function VAS, 0–1700mm Tai Chi 707.6
(246.9)
−506.8
(−635.5, −378)
0.001
Control 827.0
(258.8)
−182.2
(−321.8, −42.5)
Patient Global VAS, 1−10 cm Tai Chi 4.2
(2.1)
−3.0
(−3.9, −2.0)
0.003
Control 4.8
(2.0)
−0.8
(−1.9, 0.2)
Physician Global VAS, 1−10 cm Tai Chi 4.8
(1.7)
−3.1
(−3.9, −2.4)
0.0009
Control 5.8
(2.2)
−1.4
(−2.1, −0.8)
Chair stand test (sec) Tai Chi 40.8
(13.4)
−12.0
(−16.7, −7.4)
0.0005
Control** 35.6
(9.2)
−0.9
(−4.8, 3.0)
Proprioception (30 degree) Tai Chi 5.6
(4.2)
−2.5
(−5.0, −0.01)
0.01
Control** 4.3
(2.9)
2.1
(−0.6, 4.8)
Self efﬁcacy (0−25) Tai Chi 3.1
(1.1)
0.6
(−0.01, 1.2)
0.05
Control 3.3
(0.9)
−0.1
(−0.5, 0.3)
SF-36: PCS (0−50) Tai Chi 37.5
(8.5)
11.6
(7.6, 15.5)
0.005
Control 32.0
(8.8)
4.1
(0.7, 7.5)
SF-36: MCS (0−50) Tai Chi 51.4
(12.2)
2.1
(−4.0, 8.3)
1.0
Control 50.8
(12.6)
1.9
(−2.6, 6.5)
CES-D (0−60) Tai Chi 13.6
(11.7)
−7.4
(−11.4, −3.4)
0.009
Control 9.3
(9.2)
−0.7
(−3.9, 2.5)
*N=20 for each group. **N=19. ***Signiﬁcant improvement of Tai Chi versus attention control at
week 12. CES-D = the Center for Epidemiology Studies Depression index, SF-36 (PCS) = Short-
Form health survey (physical component summary), SF-36 (MCS) = Short-Form health survey
(mental component summary), VAS = Visual Analogue Scale.
Results: The participants had mean age 65 y (SD 7.8), mean disease
duration 10 y (SD 7.6), mean BMI 30.0 kg/m2 (SD 4.8), and median K/L
grade 4; 75% were female, 70% were white. There were no signiﬁcant
differences at baseline in demographics, radiographic score, and out-
come measures. Participants’ baseline expectations of beneﬁt from an
exercise intervention were also similar between the two groups [outcome
expectations for exercise score for Tai Chi = 4.1 (SD 0.6), controls = 4.3
(SD 0.4)]. Attendance for the 12-week assessment was 85% in the Tai
Chi group and 89% in the attention control. Participants in the Tai Chi arm
exhibited signiﬁcantly greater improvements in pain, physical function, de-
pression, self-efﬁcacy and health status (Table). Patients who continued
Tai Chi practice after 12 weeks reported durable beneﬁts in WOMAC pain
[between-group difference −150.2 (SD 116.6), p=0.04 at week 24 and
−185.3 (SD 54.1), p=0.001 at week 48] and WOMAC function [between-
group difference −572.7 (SD 257.8), p=0.02 at week 48].
Conclusions: Tai Chi is efﬁcacious for treatment of pain and physical
impairment in people with severe KOA. Further studies should be per-
formed to replicate these results and deepen our understanding of this
therapeutic modality.
A47 MEDICATIONS AND OSTEOARTHRITIS IN THE
COMMUNITY – ARE THE COMBINATIONS APPROPRIATE?
T.K. Gill1, A.W. Taylor1, C.L. Hill2. 1SA Health, Adelaide, AUSTRALIA,
2The Queen Ellzabeth Hospital, Adelaide, AUSTRALIA
Purpose: To assess the prevalence of osteoarthritis and medication
use among participants in a population-based cohort study conducted
in Australia.
Methods: The North West Adelaide Health Study is a representative
longitudinal cohort study of people aged 18 years and over living in
the northwest region of Adelaide, South Australia, Australia. The original
sample (n = 4060) was randomly selected and recruited by telephone
interview to participate in a clinic assessment. The second stage of
data collection from this cohort was undertaken between mid 2004 and
early 2006 and in this phase, information regarding the prevalence of
musculoskeletal conditions was included. The self reported prevalence
of arthritis (including osteoarthritis) was collected using a Computer As-
sisted Telephone Interview (CATI) survey. All medications that participants
were taking, including complementary and alternative medicines, were
recorded at the clinic visit.
Results: Overall, n = 3502 participants responded to the CATI component
of the study, with 7.5% (95% CI 6.6−8.4) reporting that they had been told
by a doctor that they had osteoarthritis. There was also 10.8% (95% CI
9.8−11.8) of respondents who reported that they did not know the type
of arthritis that they had. Among respondents who stated that they had
osteoarthritis, 22.3% (95% CI 17.4−28.1) were on COX-2 inhibitors and
11.0% (95% CI 7.6−15.6) were on a non steroidal anti-inﬂammatory
medication (NSAID, excluding aspirin). There were also 20.6% (95% CI
15.9−26.3) with osteoarthritis who reported that they took aspirin. Of the
respondents with osteoarthritis who took a non-selective NSAID there
were 11.2% who also took a COX-2 inhibitor and among the respondents
who took a non-selective NSAID (excluding aspirin) and/or a selective
NSAID (COX-2 inhibitor), a quarter (24.6%) also took aspirin, 7.4% took
alendronate and 3.2% took metformin. Of those with osteoarthritis and
taking any form of NSAID (excluding aspirin), 37.6% were also taking
proton pump inhibitors which might suggest gastroesophageal problems
and 37.9% had renal disease (using the Cockcroft-Gault equation to cal-
culate the glomerular ﬁltration rate (GFR), with renal disease deﬁned as
an estimated GFR of less than 60mL/min per 1.73m2). Respondents self-
reporting that they had osteoarthritis also took a variety of complementary
and alternative medicines. Overall, 13.7% (95% CI 9.9−18.8) took ﬁshoil
and 20.0% (95% CI 15.4−25.6) took glucosamine and/or chondroitin.
Conclusions: Medication is an important part of arthritis treatment and
fracture prevention, but even in those whose doctor had told them
they had arthritis, in particular osteoarthritis, opportunities to use anti-
inﬂammatory medications were missed or inappropriate medications were
used in conjunction with these drugs.
A48 GENOME-WIDE LINKAGE SCAN AND HIGH-DENSITY
ASSOCIATION STUDIES IMPLICATE CHROMOSOME 18q21
WITH GENERALIZED OSTEOARTHRITIS
J.M. Jordan1, U. Atif2, M. Chiano3, M. Doherty4, M.C. Hochberg5,
V.B. Kraus6, R. Loeser7, R.W. Moskowitz8, A.G. Wilson9, for The
GOGO Study Investigators. 1University of North Carolina, Chapel
Hill, NC, USA, 2Glaxo Smith Kline, Research Triangle Park, NC,
USA, 3Glaxo Smith Kline, Harlow, UNITED KINGDOM, 4University of
Nottingham, Nottingham, UNITED KINGDOM, 5University of Maryland,
Baltimore, MD, USA, 6Duke University, Durham, NC, USA, 7Wake
Forest University, Winston Salem, NC, USA, 8Case Western Reserve
University, Cleveland, OH, USA, 9University of Shefﬁeld, Shefﬁeld,
UNITED KINGDOM
Purpose: Osteoarthritis (OA) is characterized as a heterogeneous disor-
der with evidence of multigenic inheritance. Previous studies have identi-
ﬁed several candidate genes as well as novel loci on chromosomes 2, 7,
11 and 16 associated with OA at the hand, hip, knee and/or spine. The
goal of the Genetics of Generalized Osteoarthritis (GOGO) Study was
